VIVESTO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.285 SEK | -1.55% |
|
-9.52% | -30.06% |
| Mar. 26 | Transcript : Vivesto AB - Special Call | |
| Mar. 07 | Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Sector
Pharmaceuticals
Calendar
2024-05-22
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.06% | 13.99M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- VIVE Stock
- News Vivesto AB
- Vivesto Halts Patient Enrollment in Phase 1b Study for Prostate Cancer Treatment
